奥司他韦
扎那米韦
神经氨酸酶
神经氨酸酶抑制剂
病毒学
流感季节
人流感
病毒
微生物学
生物
医学
2019年冠状病毒病(COVID-19)
内科学
传染病(医学专业)
疾病
流感疫苗
作者
Naoki Tani,Naoki Kawai,Yong Pil Chong,Takuma Bando,Norio Iwaki,Seizaburo Kashiwagi,Hideyuki Ikematsu
标识
DOI:10.1016/j.jinf.2021.11.020
摘要
To investigate the susceptibility of epidemic influenza viruses to neuraminidase inhibitors (NAIs) and the emergence of resistant viruses after treatment, a prospective, observational study was done in the 2019-20 Japanese influenza season.Influenza viruses were isolated before and twice after treatment, the first at day 5 and the second at day 10. The 50% inhibitory concentrations (IC50s) to oseltamivir, zanamivir, peramivir, and laninamivir were measured and compared with those of 2010-11 to 2018-19 seasons. NA amino acid sequences were analyzed by next generation sequencing (NGS).The IC50 geometric means of the NAIs for 128 A(H1N1)pdm09, 2 A(H3N2), and 33 B were comparable to those of the previous seasons. Only 2 (1.6%) A(H1N1)pdm09 with significantly high IC50 to oseltamivir were found pretreatment. No A(H3N2) or B had resistance. Treatment-emergent oseltamivir resistance was found in 2 among 33 oseltamivir-treated A(H1N1)pdm09, only at the second follow-up. The NGS indicated a rapid increase in the proportion of H275Y to wild type, from 0% to almost 100% between days 5 and 10.These results suggest the continued effectiveness of these NAIs for epidemic influenza in Japan. Treatment-emergent resistant H275Y A(H1N1)pdm09 viruses were detected after oseltamivir treatment, rapidly replacing the wild type.
科研通智能强力驱动
Strongly Powered by AbleSci AI